^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ONCR-021

i
Other names: ONCR-021, coxsackievirus A21, CVA21
Associations
Trials
Company:
Oncorus
Drug class:
Immunostimulant
Related drugs:
Associations
Trials
over2years
Overcoming the Challenge of RNA Therapeutics for the Treatment of Cancer, Development of Lipid Nanoparticle-Formulated RNA Viral Immunotherapy (ASGCT 2022)
Interestingly, the in vivo efficacy of ONCR-021 and ONCR-788 is maintained even in the presence of neutralizing antibodies against CVA21 and SVV, suggesting that administration of LNP-formulated RNA immunotherapy enables the repeated and systemic exposure of disseminated tumors to potently oncolytic viruses. These data highlight an innovative RNA therapeutic modality for the IV treatment of tumors which overcomes the limitations of other RNA-based therapeutics and supports ONCR-021 and ONCR-788 into IND-enabling studies.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Cavatak (gebasaxturev) • ONCR-021 • ONCR-788